8 November, 2023

FDA’s New Guidance on Biosimilar Labeling: A Step Towards Clarity and Confidence

The FDA’s new guidance on biosimilar labeling marks a significant change for companies managing biosimilar approvals and pharmacy substitutions. By adopting a unified “Biosimilarity Statement,” the FDA aims to streamline labeling, removing separate interchangeability statements and reinforcing that all biosimilars meet the same stringent safety and efficacy standards.

This article delves into the key benefits, including simplified prescriber processes, improved pharmacist guidance, and clearer communication of biosimilar interchangeability standards, helping companies navigate a more efficient and accessible regulatory landscape.

Please enter your details to get access to the content









    Discover how we can help you

    Close Popup

    This site uses cookies to personalise and customise your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

    Close Popup
    Privacy Settings saved!
    Privacy Settings

    When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

    These cookies are necessary for the website to function and cannot be switched off in our systems.

    Technical Cookies
    In order to use this website we use the following technically required cookies
    • wordpress_test_cookie
    • wordpress_logged_in_
    • wordpress_sec

    Cloudflare
    In order to use this website we use the following technically required cookies
    • __cfduid

    Decline all Services
    Save
    Accept all Services